This is a working overview of cyclic heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-13 and is reviewed periodically as new material appears.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
| Property | Value | Notes |
|---|---|---|
| Solubility class | Freely soluble in water | Also soluble in DMSO and some alcohols |
| Typical storage temperature | -20 C or below | Desiccated, protected from light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
| Typical reported purity | 95 percent or higher | Reference-grade material |
| Common synonyms | PT-141 | Also called bremelanotide acetate |
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
=== EC 1.2.5 With a quinone or similar compound as acceptor === EC 1.2.5.1: pyruvate dehydrogenase (quinone) EC 1.2.5.2: aldehyde dehydrogenase (quinone) EC 1.2.5.3: aerobic carbon monoxide dehydrogenase
=== Ammonia === Increased circulating levels of ammonia may alter brain function and result in fatigue. One hypothesized reason that BCAAs fail to increase exercise performance is due to increased oxidation of BCAAs in supplementation that results in increased fatigue, canceling out the effects on serotonin receptors.
=== Charge-exchange chemical ionization === This is also similar to CI and the difference lies in the production of a radical cation with an odd number of electrons. The reagent gas molecules are bombarded with high energy electrons and the product reagent gas ions abstract electrons from the analyte to form radical cations. The common reagent gases used for this technique are toluene, benzene, NO, Xe, Ar and He. Careful control over the selection of reagent gases and the consideration toward the difference between the resonance energy of the reagent gas radical cation and the ionization energy of the analyte can be used to control fragmentation. The reactions for charge-exchange chemical ionization are as follows.
Sources: en.wikipedia.org
== Further reading == Claire Dunn, Carl Jung: Wounded Healer of the Soul (2000) J. Halifax, Shaman: The Wounded Healer (1982) Nouwen, Henri J. M. (1979-02-02). The Wounded Healer: Ministry in Contemporary Society. Doubleday. ISBN 978-0-385-14803-0. John Merchant, Shamans and Analysts: New Insights on the Wounded Healer (2011) Daryl Sharp, The Jung Lexicon (Toronto) David Sedgwick, The Wounded Healer: Countertransference from a Jungian Perspective (1994)
AM-2201 (1-(5-fluoropentyl)-3-(1-naphthoyl)indole) is a recreational designer drug that acts as a potent but nonselective full agonist for the cannabinoid receptor. It is part of the AM series of cannabinoids discovered by Alexandros Makriyannis at Northeastern University.
Beta decay leaves the mass number unchanged, so the change of nuclear spin must be an integer. However, the electron spin is 1/2, hence angular momentum would not be conserved if beta decay were simply electron emission. From 1920 to 1927, Charles Drummond Ellis (along with Chadwick and colleagues) further established that the beta decay spectrum is continuous. In 1933, Ellis and Nevill Mott obtained strong evidence that the beta spectrum has an effective upper bound in energy. Niels Bohr had suggested that the beta spectrum could be explained if conservation of energy was true only in a statistical sense, thus this principle might be violated in any given decay. However, the upper bound in beta energies determined by Ellis and Mott ruled out that notion. Now, the problem of how to account for the variability of energy in known beta decay products, as well as for conservation of momentum and angular momentum in the process, became acute. In a famous letter written in 1930, Wolfgang Pauli attempted to resolve the beta-particle energy conundrum by suggesting that, in addition to electrons and protons, atomic nuclei also contained an extremely light neutral particle, which he called the neutron. He suggested that this "neutron" was also emitted during beta decay (thus accounting for the known missing energy, momentum, and angular momentum), but it had simply not yet been observed. In 1931, Enrico Fermi renamed Pauli's "neutron" the "neutrino" ('little neutral one' in Italian).
=== Sales === There are currently 6,157 total Domino's units in the United States, and of those 5,815 of those are franchised units. In 2018, the Average Weekly Unit Sales (AWUS) for franchised units was $22,045, showing a consistent increase over the past five years. Per year, this amounts to an average of over a million dollars in sales. Domino's EBITDA was 15.0% for stores making more than $25,000. The vast majority of stores fell under this category, more than 1,500 units. According to Domino's 2019 income statement, their net income was just over $400,000. The initial franchise fee for a Domino's franchise is $10,000, the royalty fee is 5.5% of the store's weekly sales, and the advertising payment is 4% of the store's weekly sales.
Sources: en.wikipedia.org
=== Bektashism under Ottoman rule === The Bektashis acquired political importance in the 15th century when the order dominated the Janissary Corps. The branch became widespread in the Ottoman Empire, with its lodges scattered throughout Anatolia and the Balkans. It became the official order of the Janissaries, the elite infantry corps of the Ottoman military. Therefore, they also became mainly associated with Anatolian and Balkan Muslims of Eastern Orthodox convert origin, mainly Albanians and northern Greeks (although most leading Bektashi babas were of southern Albanian origin). In 1826, the Bektashi order was banned throughout the Ottoman Empire by Sultan Mahmud II for having close ties with the Janissary corps. Many Bektashi dervishes were exiled, and some were executed, while tekkes were destroyed and their revenues were confiscated. This decision was supported by the Sunni religious elite and the leaders of other, more orthodox, Sufi orders. Bektashis slowly regained freedom with the coming of the Tanzimat In the Balkans, the Bektashi order had a considerable influence on the Islamization of many areas, primarily Albania and Bulgaria, as well as parts of Macedonia, particularly among Ottoman-era Greek Muslims from western Greek Macedonia such as the Vallahades. By the 18th century, Bektashism began to gain a considerable hold over southern Albania and northwestern Greece (Epirus and western Greek Macedonia).
The special forces site, located near a compound associated with Mullah Omar, was described as one of Akhundzada's most trusted units. Afghan locals also reported an airstrike in Spin Boldak District, while armed clashes resumed between Taliban forces and Pakistani border guards in Khost. However, a Taliban spokesperson claimed that no one had been hurt in the airstrikes and that they had caused only limited damage to a drug rehabilitation centre and an empty container. A police constable was injured while repelling a militant attack on a police post in Dera Ismail Khan District.
=== Historical taxonomy === The taxonomic history of Xanthoria parietina begins in 1753 with Carl Linnaeus, who first described it as Lichen parietinus in his landmark work Species Plantarum. In his brief diagnosis, Linnaeus characterized it as a foliose lichen with curled yellowish-brown lobes and a matching surface, citing Dillenius's earlier depiction and noting its broad European distribution on walls, rocks, and wood. Linnaeus's original specimens of Lichen parietinus are preserved in the Linnaean Herbarium (LINN), both labeled with his Species Plantarum number 25. These specimens have caused taxonomic confusion, as one actually corresponds to Rusavskia elegans (formerly Xanthoria elegans), while the other has features resembling Xanthoria ectaneoides. A separate specimen in his Flora Suecica collection was later reassigned to X. parietina. Due to these inconsistencies, taxonomists designated the illustration cited by Linnaeus from Dillenius (1742) as the lectotype, with a corresponding specimen in the Oxford herbarium (OXF) designated epitype.
Sources: en.wikipedia.org
The peptide is polar and charged, and reversed-phase chromatography with acidic mobile phases resolves it well from related substances. Ultraviolet detection near 214 nm gives adequate sensitivity without derivatisation.
Aqueous solutions are subject to oxidation and hydrolysis, so concentration and pH drift can occur even under refrigeration. Solid, dry material held cold and desiccated degrades far more slowly.
Mass spectrometry separates the parent from analogues that differ by a single modification, such as an amide versus acid terminus. Retention time alone is less reliable because closely related peptides can co-elute.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.